Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 19;418:129392. doi: 10.1016/j.cej.2021.129392

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 8 — Immune protection of different administration routes of bionic-virus nanovaccine. (a) Representative flow cytometric analysis images of CD4⁺CD3⁺ T cells in BALF. (b) Relative quantification of CD4⁺CD3⁺ T cells in BALF. (c) Representative flow cytometric analysis images of CD44⁺CD62L⁺ TCM cells in BALF. (d) Relative quantification of CD44⁺CD62L⁺ TCM cells in BALF. (e) Representative flow cytometric analysis images of CD138⁺CD45⁺ B cells in spleen. (f) Relative quantification of CD138⁺CD45⁺ B cells in spleen. (g) Anti-RBD IgG titer. (h) Anti-RBD sIgA titer. (i) PsV IC₅₀ inhibition titer of BALF. (j) Anti-RBD sIgA titer of mice during the five months evaluation period. (I: PBS, II: Intramuscular Injection, III: Intraperitoneal Injection, IV: Nasal Delivery).